Avacta Group Plc (AIM: AVCT)
Health Care · Biotechnology · GB
£0.68
+6.25% today · +34.7% 1Y
Avacta Group Plc (AIM: AVCT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $434.13M.
Over the last twelve months the share price has gained 34.7%, trading between 0.47 and 0.92.
Tweenvest scores Avacta Group Plc across four factors: quality 11/100, growth 31/100. Its strongest factor is growth.
AVCT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $434.13M
- Revenue (TTM)
- $152.09K
- P/E
- —
- EPS
- -0.10
- Dividend yield
- —
- Beta (5Y)
- -0.11
- 52-week high
- £0.92
- 52-week low
- £0.47
- Avg volume (3M)
- —
- Shares outstanding
- 468.40M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $142.62 | -1.69% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.